Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design-Reference-Cited by-同舟云学术

Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design

Published:2011-12-02 Issue:6060 Volume:334 Page:1289-1293
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Diskin Ron¹,Scheid Johannes F.²³,Marcovecchio Paola M.¹,West Anthony P.¹,Klein Florian²,Gao Han¹,Gnanapragasam Priyanthi N. P.¹,Abadir Alexander²,Seaman Michael S.⁴,Nussenzweig Michel C.²⁵,Bjorkman Pamela J.¹⁶

Affiliation:

1. Division of Biology, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA.

2. Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.

3. Charite Universitätsmedizin, D-10117 Berlin, Germany.

4. Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

5. Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.

6. Howard Hughes Medical Institute, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA.

Abstract

Structural analysis of an HIV antibody reveals residues important for neutralization breadth and potency.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference41 articles.

1. HIV Vaccine Research: The Way Forward

2. Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination

3. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus

4. The immune response during acute HIV-1 infection: clues for vaccine development

5. Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design

Cited by 338 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env;Journal of Virology;2024-09-06

2. HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy;2024-07-12

3. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives;Clinical Microbiology Reviews;2024-06-13

4. Nanocapsules Comprised of Purified Protein: Construction and Applications in Vaccine Research;Vaccines;2024-04-12

5. High affinity mAb infusion can enhance maximum affinity maturation during HIV Env immunization;iScience;2024-04